Hybio Pharmaceutical (300199.SZ): Cabergoline raw material obtained EU DCP approval.

Hybio Pharmaceutical (300199.SZ) announced that on May 29, 2026, the company received the EU DCP approval document issued by the reference member state Ireland (HPRA). The company's production of Carboprost raw material drug obtained approval through the European Decentralized Procedure (DCP). Carboprost, as a new generation of potent uterotonic, works by binding to the uterine smooth muscle oxytocin receptors, inducing rhythmic contractions of the uterus, and increasing the frequency and intensity of contractions. It has receptor saturation characteristics. It is a synthetic long-acting oxytocin that has unique advantages in reducing the incidence of postpartum bleeding. Carboprost has a long duration of action, stronger uterine contractions, and can reduce the probability of additional use of therapeutic uterotonic agents. Its potency is 10 times that of oxytocin, and it is safer in terms of maintaining stable cardiac contraction and relaxation pressure.